Skip to Main Content

Imaging SV2A in mood disorders

Conditions

Mental Health & Behavioral Research

What is the purpose of this trial?

The goal of the study is to determine whether there are alterations in synaptic vesicle glycoprotein 2A (SV2A), a protein expressed ubiquitously in synaptic vesicles, in depression and anxiety and whether ketamine, an N-Methyl-D-aspartate (NMDA) antagonist, normalizes SV2A density at time of its greatest anti-depressant response. We will conduct an examination of SV2A and associated consequences using neuroreceptor imaging and behavioral techniques.

  • Trial with
    Nancy Taylor Foundation for Chronic Diseases, Inc.
  • Start Date
    03/18/2016
  • End Date
    03/14/2022
Trial Image

For more information about this study, contact:

Sarah DeBonee

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    05/15/2018
  • Study HIC
    #1511016789